Show simple item record

dc.contributor.advisorHarrison, Roger
dc.contributor.authorSouthard, Benjamin
dc.date.accessioned2019-08-07T17:31:51Z
dc.date.available2019-08-07T17:31:51Z
dc.date.issued2019
dc.identifier.urihttps://hdl.handle.net/11244/321127
dc.description.abstractOne of the most ubiquitous biomarkers of cancer is phosphatidylserine. It is expressed exclusively on the inner membrane leaflet of healthy vasculature, but tumor endothelium externalizes phosphatidylserine, taking advantage of its immunosuppressive signaling role. Annexin V is a small membrane binding protein that selectively binds to externally expressed phosphatidylserine and induces endocytosis. An annexin V-drug conjugate has been synthesized and characterized that is designed to deliver the cytotoxic drug payload to tumor cells. The cytotoxic activity was investigated in vitro using three breast cancer and two leukemia cell lines. This thesis describes the synthesis and characterization and reports the results of the in vitro experiments.en_US
dc.languageen_USen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjecttargeted therapyen_US
dc.subjectcanceren_US
dc.subjectdrug conjugateen_US
dc.titleNOVEL TARGETED ANNEXIN V - DRUG CONJUGATE FOR CANCER CHEMOTHERAPEUTIC TREATMENTen_US
dc.contributor.committeeMemberNollert, Matthias
dc.contributor.committeeMemberSikavitsas, Vassilios
dc.date.manuscript2019
dc.thesis.degreeMaster of Scienceen_US
ou.groupGallogly College of Engineering::Stephenson School of Biomedical Engineeringen_US


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International